Related references
Note: Only part of the references are listed.
Review
Chemistry, Multidisciplinary
Can-rong Wu et al.
Summary: The tireless efforts of scientists globally have greatly enhanced our understanding of the biology of coronaviruses, with structural biology playing a key role in uncovering structures and functions of viral proteins and guiding drug and vaccine development. The importance of structure in drug discovery to combat COVID-19 has been highlighted, while attention is needed on the implications of Omicron variants on existing vaccines and antibody therapies.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Biochemistry & Molecular Biology
Cecylia S. Lupala et al.
Summary: The COVID-19 pandemic caused by SARS-CoV-2 virus has resulted in over 270 million infections and 5.3 million deaths worldwide. The emergence of the Omicron variant has raised concerns about reducing vaccine efficacy and neutralizing antibodies due to its numerous mutations. Analysis indicates that the Omicron variant binds more strongly to the human ACE2 protein, with mutations at the ACE2-RBD interface enhancing tight binding through increased hydrogen bonding interactions and enlarged buried solvent accessible surface area.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Medical Laboratory Technology
Giuseppe Lippi et al.
Summary: Measuring the level of protection provided by anti-SARS-CoV-2 antibodies is a reliable approach for predicting biological protection against COVID-19. However, the vast mutations in SARS-CoV-2 may compromise the reliability of current commercial immunoassays.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Article
Immunology
Lu Lu et al.
Summary: Immune sera from BNT162b2 and Coronavac recipients showed reduced neutralizing antibody titers against the omicron variant. The presence of the spike R346K mutation did not affect the neutralization susceptibility.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Infectious Diseases
Thibault Fiolet et al.
Summary: Overall, COVID-19 vaccines have high efficacy against the original strain and variants of concern, with rare serious adverse events. However, prices vary significantly for different vaccines.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Editorial Material
Virology
Farid Rahimi et al.
Article
Pediatrics
Tanu Singhal
Summary: COVID-19 has caused a significant number of cases and deaths worldwide, and the omicron variant is currently driving a surge in cases globally. Despite some protection provided by previous infection and vaccination, the impact of omicron on the healthcare system, economy, and children's health has been substantial. It is crucial for governments to make rational decisions to navigate through this crisis.
INDIAN JOURNAL OF PEDIATRICS
(2022)
Editorial Material
Infectious Diseases
Eskild Petersen et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Saathvik R. Kannan et al.
Summary: The Omicron variant of concern (VOC) has a large number of mutations, with 46 high prevalence mutations, which may affect the binding affinities of antibodies to the S protein.
JOURNAL OF AUTOIMMUNITY
(2022)
Review
Virology
Vikram Thakur et al.
Summary: The emergence of the OMICRON variant of SARS-CoV-2 has become a global concern, spreading to over 77 countries and sparking hypotheses about its origins and infectivity. The detection of mutations in the Spike protein's RBD region is concerning, as it may surpass vaccine immunity.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Virology
Lulan Wang et al.
Summary: The discovery of the Omicron variant has sparked global concerns about its mutations, transmission, and immune escape properties. Current research suggests that the variant may impact viral infectivity and host immunity, and it may evolve from clade 20B.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Virology
Shailendra K. Saxena et al.
Summary: Omicron is the latest variant of concern of SARS-CoV-2, with more mutations compared to the previous Delta variant. Fifteen of these mutations are located in the receptor-binding domain of the spike glycoprotein, which may affect transmissibility, infectivity, antibody neutralization, and vaccine efficacy. The study provides insights into the mutational hotspots of Omicron and its global impact on transmission, testing, and immunity.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Letter
Virology
Stefano Pascarella et al.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Medicine, General & Internal
Nicole Wolter et al.
Summary: According to data analysis from South Africa, individuals infected with the omicron variant have a lower likelihood of hospitalization compared to those infected with non-omicron variants. Furthermore, individuals infected with the omicron variant have a lower odds of severe disease compared to individuals infected with the earlier delta variant.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Biochemistry & Molecular Biology
Laura A. VanBlargan et al.
Summary: The emergence of the B.1.1.529 Omicron variant raises concerns about the efficacy of antibody countermeasures. This study shows that some of the antibodies currently in clinical use may lose their ability to neutralize the Omicron variant.
Article
Biochemistry & Molecular Biology
Henning Gruell et al.
Summary: This study demonstrates that neutralization of the SARS-CoV-2 Omicron variant is greatly reduced in individuals who received two doses of the COVID-19 vaccine or have recovered from the disease, but is significantly increased after a booster vaccine dose.
Article
Biochemistry & Molecular Biology
Eddy Perez-Then et al.
Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.
Article
Clinical Neurology
Shivam Bhola et al.
Summary: This review focuses on the various neurological disorders associated with the central nervous system and peripheral nervous system in relation to the COVID-19 disease caused by the SARS-CoV-2 virus. It examines disorders such as cytokine release syndrome, encephalitis, acute stroke, Bell's palsy, as well as psychological manifestations. The review also explores cognitive impairment, drug addiction disorders, mood and anxiety disorders, and post-traumatic stress disorder. The exact association and mechanism of the SARS-CoV-2 virus with neurological disorders are yet to be clarified, highlighting the need for further research to understand the neurological impact of COVID-19.
NEUROLOGICAL SCIENCES
(2022)
Review
Virology
Ikbel Hadj Hassine
Summary: Since the outbreak of Covid-19 in December 2019, there have been over 242 million confirmed cases and nearly 5 million deaths worldwide. Nine Covid-19 vaccine candidates based on the original Wuhan-Hu-1 strain have efficacy over 50%, but face challenges from emerging variants and rare adverse events. Additional effective vaccines are still needed to meet global demand, with promising candidates progressing to clinical studies.
REVIEWS IN MEDICAL VIROLOGY
(2022)
Article
Immunology
Ritthideach Yorsaeng et al.
Summary: The immune response after the AZD1222 booster in individuals who received the two-dose CoronaVac vaccine was found to be limited, with lower neutralizing activity against the wild type and variants. However, the AZD1222 booster significantly enhanced the immune response, resulting in higher antibody levels and neutralizing activity.
Editorial Material
Surgery
Om Prakash Choudhary et al.
INTERNATIONAL JOURNAL OF SURGERY
(2022)
Article
Public, Environmental & Occupational Health
Naushad Ahmad Khan et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2022)
News Item
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Medicine, Research & Experimental
Dinah V. Parums
MEDICAL SCIENCE MONITOR
(2022)
Review
Public, Environmental & Occupational Health
Jonaid Ahmad Malik et al.
Summary: This article introduces the mutations of SARS-CoV-2 coronavirus and the effectiveness of vaccines, with a focus on the spike protein and vaccine design. Currently, there are multiple vaccine candidates undergoing clinical trials, but their efficacy against newly emerged variants still needs further examination. The article emphasizes the importance of understanding the mutations of the coronavirus in designing better vaccines and underscores the significance of preventive measures.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)
Article
Pediatrics
Jeane Cloete et al.
Summary: South Africa has experienced a significant increase in COVID-19 cases, especially among pediatric patients, with the predominant variant being the SARS-CoV-2 omicron strain. The rise in pediatric COVID-19 cases and hospitalizations has occurred ahead of adult hospitalizations, highlighting the need for ongoing monitoring to understand the long-term effects of the omicron variant on children and adolescents.
LANCET CHILD & ADOLESCENT HEALTH
(2022)
Article
Biophysics
Yuanhao Liang et al.
Summary: This study designed CRISPR RNAs targeting the spike protein of the Omicron variant and developed a rapid assay based on CRISPR-Cas12a to detect and differentiate Omicron variant from other SARS-CoV-2 variants and common respiratory pathogens. The assay showed a low limit of detection and could be easily implemented in laboratories to monitor and track the spread of the Omicron variant.
BIOSENSORS & BIOELECTRONICS
(2022)
Review
Medicine, Research & Experimental
Ahmed Ali Al-Qahtani
Summary: This narrative review examines genomic mutations in SARS-CoV-2 and how they impact the severity and progression of COVID-19. It discusses notable mutations associated with different proteins in the virus, as well as emerging variants in different countries. These mutations have the potential to influence viral replication and disease dynamics, providing valuable insights for therapeutic development.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2022)
Article
Virology
Yongzheng Li et al.
Summary: The study indicates that T-cell responses from individuals who received CoronaVac vaccination provided significant protection against the SARS-CoV-2 Omicron variant, especially with booster doses. Some Omicron mutations may slightly weaken T-cell responses.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Multidisciplinary Sciences
Roanne Keeton et al.
Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The SARS-CoV-2 Omicron variant evades antibody-mediated immunity and exhibits enhanced affinity for host cells due to accumulation of spike mutations and remodeling of interactions with the ACE2 receptor.
Article
Virology
Marco Gerdol et al.
Summary: Tracking the evolution of SARS-CoV-2 is crucial in the current pandemic situation. The virus acquires mutations at a slower rate compared to other RNA viruses, but the widespread circulation of SARS-CoV-2 in the human population has led to the emergence of several variants of concern. These variants carry multiple nonsynonymous mutations in the spike glycoprotein, potentially conferring resistance to neutralizing antibodies and affecting viral infectivity. In addition, some variants have deletion regions that overlap with antibody epitopes. This study highlights a recurrent insertion region in the N-terminal domain of the spike protein, which warrants further investigation into its effects on spike structure and viral infectivity.
Review
Microbiology
Gary McLean et al.
Summary: The emergence of new variants of SARS-CoV-2 has raised concerns about the impact on vaccination programs. Current vaccines are effective against some variants, but effectiveness varies. Booster programs can restore protection against infection and symptomatic disease, but the effectiveness may decrease over time. Antibodies may have reduced neutralizing activity against certain variants, but T-cell responses remain relatively stable.
Article
Virology
Laura Torre-Fuentes et al.
Summary: This study investigated the impact of genetic variants on SARS-CoV-2 infection susceptibility, finding low polymorphism in the ACE2 gene and a potential association of variants in the TMPRSS2 gene with COVID-19. Despite a limited number of patients, these findings are important for understanding individual susceptibility to viral infections.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Prabin Baral et al.
Summary: The surges of the more infectious Delta variant have intensified the health crisis, but current vaccines offer protection against it. However, the Delta variant can evade the immune system to some extent by reducing the receptivity of neutralizing antibodies.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Infectious Diseases
Antonin Bal et al.
Summary: The study reported the strategy leading to the first detection of the variant of concern 202012/01 (VOC) in France, by screening for mutations such as Delta H69/Delta V70 associated with VOC and identifying co-occurring mutations like S:N501Y.
Article
Chemistry, Physical
Rui Wang et al.
Summary: Understanding the evolution of SARS-CoV-2 is crucial, with recent studies revealing that vaccine-breakthrough or antibody-resistant mutations are becoming dominant mechanisms, particularly correlated with vaccination rates in Europe and America. It is anticipated that these mutations will play a major role in evolution as more people worldwide are vaccinated or infected.
JOURNAL OF PHYSICAL CHEMISTRY LETTERS
(2021)
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Behnaz Bakhshandeh et al.
Summary: The third pandemic of coronavirus infection, COVID-19, started recently in China. The main pathogenesis includes severe pneumonia, with various factors potentially influencing mortality and infection rates. Mutations and genetic variabilities of the virus, along with host genetic susceptibility, can impact the clinical features of COVID-19.
MICROBIAL PATHOGENESIS
(2021)
Article
Multidisciplinary Sciences
Louise Dyson et al.
Summary: The viral reproduction of SARS-CoV-2 provides opportunities for acquiring advantageous mutations, and different mathematical models show that the epidemiological trajectories of potential VOCs depend on their transmissibility and immune escape capability. Variants with transmission advantages or immune escape properties can generate waves of infections, while variants with lower transmissibility but partial immune escape may only be revealed after further relaxation of control measures.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Renhong Yan et al.
Summary: This study investigated the structural basis for the potent neutralizing activity of nAbs against SARS-CoV-2, finding that the bivalent binding of full-length IgG associates with more RBDs in the up conformation, leading to enhanced neutralization and shedding of the S1 subunit from the S protein. Comparing a large number of nAbs revealed common and unique structural features associated with their potent neutralizing activities.
Review
Microbiology
Mehrnoosh Moghaddar et al.
Summary: The COVID-19 pandemic has infected millions and caused numerous deaths globally. The Delta and Lambda variants exhibit high infectivity and reduced responsiveness to vaccines. Future therapeutic strategies may focus on epitope stability, conservation of N protein, and the novel intracellular antibody receptor TRIM21.
Editorial Material
Oncology
Nicholas E. Ingraham et al.
Summary: The recently discovered Omicron variant of SARS-CoV-2 has raised global concern due to its more than 50 mutations and potential impact on public health. Current knowledge about this viral variant is limited, and there is a need to rapidly address key questions surrounding it.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Immunology
Velayudhan Mohan Kumar et al.
Summary: India has started a large-scale COVID-19 vaccination program, with four domestically developed vaccines already approved. The country has the capacity to meet its vaccination needs and has established sufficient manpower and cold-chain infrastructure for the initial phase. Additionally, India has taken urgent measures to expand vaccine manufacturing capacity and implemented an efficient digital system for vaccine administration.
Review
Immunology
Lianlian Bian et al.
Summary: The Delta variant has caused a new wave of COVID-19 epidemic, requiring a higher proportion of the population to be vaccinated to reduce disease burden. Existing vaccines have shown decreased protective efficacy against the Delta variant, with a decline in neutralizing antibody titers post-vaccination. Accelerating vaccine coverage and intervention measures like mask-wearing are effective ways to control the spread of the Delta variant.
EXPERT REVIEW OF VACCINES
(2021)
Review
Biochemistry & Molecular Biology
Edyta Janik et al.
Summary: COVID-19 is a respiratory disease caused by SARS-CoV-2, for which finding effective drugs remains a urgent target for the global scientific community. The pathogenesis is mainly related to virus replication and excessive immune/inflammatory response. Treatment options include antiviral and immunomodulatory/anti-inflammatory agents.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Jiahui Chen et al.
Summary: The ongoing vaccination and development of intervention offer hope to end the global COVID-19 pandemic, but emerging SARS-CoV-2 variants could compromise existing vaccines and antibody therapies. Studies on potential threats from mutations are limited, and the impact on clinical trial antibodies is largely unknown.
JOURNAL OF MOLECULAR BIOLOGY
(2021)
Letter
Biochemistry & Molecular Biology
Zain Chagla et al.
Review
Genetics & Heredity
Kaiming Tao et al.
Summary: The emergence of multiple SARS-CoV-2 variants has significant impacts on the epidemiological and clinical aspects of the COVID-19 pandemic, including increased virus transmission rates, heightened risk of reinfection, and reduced effectiveness of neutralizing antibodies and vaccines. These variants have introduced new challenges to COVID-19 research, necessitating additional avenues of laboratory, epidemiological, and clinical studies.
NATURE REVIEWS GENETICS
(2021)
Review
Virology
Anna Winger et al.
Summary: The high sequence identity of the initial SARS-CoV-2 samples collected in Wuhan in December 2019 did not predict the emergence of novel variants in different regions around the world. The viral spike receptor has two areas of high mutagenic plasticity, with mutations mainly focusing on the N-terminal domain and receptor binding domain. The evolution of spike mutations, including the characteristic D614G mutation, continues to drive the development of new variants.
Article
Cell Biology
Bo Meng et al.
Summary: The Delta H69N70 mutation in SARS-CoV-2 spike protein increases infectivity and partially rescues immune escape mutations that impair infectivity. Continued surveillance and research on deletions with functional effects are necessary.
Article
Microbiology
Jiri Zahradnik et al.
Summary: In vitro evolution of the SARS-CoV-2 spike protein receptor-binding domain successfully generated a high-affinity variant effective in inhibiting virus infection. Mutations present in more transmissible viruses were preferentially selected, and increased affinity to ACE2 was positively correlated with the incidence of RBD mutations in the population. The study also identified mutations with potential higher infectivity, and the high-affinity RBD variant showed efficacy in inhibiting infection in vitro and reducing clinical disease in a hamster model of SARS-CoV-2 challenge.
NATURE MICROBIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Renuka Raman et al.
Summary: SARS-CoV-2 is the cause of the COVID-19 pandemic, with its variants posing challenges to containment efforts. Individuals with dysregulated immune response and comorbidities are more susceptible to infection, and research on various vaccines and treatments is ongoing to address this challenge.
Review
Medicine, Research & Experimental
Lauren Forchette et al.
Summary: This review article examines the immunological mechanisms of SARS-CoV-2 virus and vaccines, discusses key variants and mutations driving the current pandemic, and explores new technologies being developed for prevention, treatment, and detection of the virus. It provides crucial information on virology, vaccines, drugs, and variant strains, aiming to benefit healthcare professionals and researchers in understanding and managing COVID-19 during the pandemic.
CURRENT MEDICAL SCIENCE
(2021)
Review
Medicine, General & Internal
Cesar M. J. A. Metzger et al.
Summary: The new SARS-CoV-2 Omicron variant has been declared a Variant of Concern due to important mutations in the viral spike protein, especially in the receptor-binding domain. The spread of this variant is being investigated with the first cases detected in Switzerland. Questions have been raised about the effectiveness of PCR assays and specific features for identifying Omicron samples, with guidance provided in this minireview.
SWISS MEDICAL WEEKLY
(2021)
Letter
Biochemistry & Molecular Biology
Xiantao Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Medicine, Research & Experimental
Xuemei He et al.
Summary: The new SARS-CoV-2 variant B.1.1.529 named Omicron, reported in South Africa, has raised global concerns after being designated as a variant of concern by the WHO. With a high number of mutations, including 15 in the spike receptor-binding domain, the Omicron variant shares similarities with previous VOCs, sparking worries about its transmissibility and immune evasion.
Review
Immunology
Hyunjhung Jhun et al.
Summary: As of September 21, 2021, over 228 million cases of COVID-19 have been reported worldwide, resulting in over 4 million deaths. The predominant circulating variants of concern are alpha, beta, gamma, and delta, originating from different countries like the UK, South Africa, Brazil/Japan, and India, respectively. These variants exhibit unique mutations in the spike gene, which may impact their infectivity and pathogenicity.
Article
Medicine, Research & Experimental
Cai He et al.
Summary: The study found that the S1-Mut antigens were more effective in inhibiting ACE2 binding in the B.1.351 variant. Additionally, the bivalent vaccine exhibited ideal neutralization properties against the wild-type and B.1.351 variant, as well as other variants.
Review
Environmental Sciences
Y. R. Rastogi et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL SCIENCE AND TECHNOLOGY
(2020)
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Article
Multidisciplinary Sciences
M. Rafiul Islam et al.
SCIENTIFIC REPORTS
(2020)
Article
Immunology
Susanna K. P. Lau et al.
EMERGING MICROBES & INFECTIONS
(2018)
